US 12,247,223 B2
Human liver-like three-dimensional structure, method for evaluating hepatotoxicity and human liver-like complex
Toshihiko Maekawa, Tokyo (JP); Eri Nagao, Tokyo (JP); Izumi Ide, Tokyo (JP); and Sakura Kajiyama, Tokyo (JP)
Assigned to CYFUSE BIOMEDICAL K.K., Tokyo (JP)
Appl. No. 17/432,029
Filed by CYFUSE BIOMEDICAL K.K., Tokyo (JP)
PCT Filed Feb. 21, 2020, PCT No. PCT/JP2020/007156
§ 371(c)(1), (2) Date Aug. 18, 2021,
PCT Pub. No. WO2020/171220, PCT Pub. Date Aug. 27, 2020.
Claims priority of application No. 2019-030240 (JP), filed on Feb. 22, 2019.
Prior Publication US 2022/0315899 A1, Oct. 6, 2022
Int. Cl. C12N 5/071 (2010.01); C12Q 1/6883 (2018.01); G01N 33/50 (2006.01)
CPC C12N 5/0671 (2013.01) [C12Q 1/6883 (2013.01); G01N 33/5014 (2013.01); G01N 33/5067 (2013.01); C12N 2513/00 (2013.01); C12Q 2600/178 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A human liver-like three-dimensional construct comprising a heterospheroid formed of an aggregate of human hepatocytes and human-derived cells other than the human hepatocytes,
wherein the other human-derived cells comprise human hepatic stellate cells;
the ratio of the number of the other human-derived cells to the number of the human hepatocytes is 0.01 or higher but lower than 1; and
wherein a cluster of the human hepatic stellate cells has a maximum projected area (equivalent circular) diameter of 100 μm.